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Abstract
Type 1 diabetes is a chronic autoimmune disease characterised by insulin deficiency and resultant 
hyperglycaemia. Knowledge of type 1 diabetes has rapidly increased over the past 25 years, 
resulting in a broad understanding about many aspects of the disease, including its genetics, 
epidemiology, immune and β-cell phenotypes, and disease burden. Interventions to preserve β 
cells have been tested, and several methods to improve clinical disease management have been 
assessed. However, wide gaps still exist in our understanding of type 1 diabetes and our ability to 
standardise clinical care and decrease disease-associated complications and burden. This Seminar 
gives an overview of the current understanding of the disease and potential future directions for 
research and care.
Introduction
At first consideration, type 1 diabetes pathophysiology and management might seem 
straightforward; however, the more that is learnt about the disease, the less it seems is truly 
known. Improved understanding of the disease’s pathogenesis has not led to a single 
unifying Koch’s postulate for all cases. What once seemed like a single autoimmune 
disorder, with roots in T-cell mediated attack of insulin-producing β cells, is now recognised 
to result from a complex interplay between environmental factors and microbiome, genome, 
metabolism, and immune systems that vary between individual cases.
Despite known genetic underpinnings, most people who are diagnosed with type 1 diabetes 
do not have a relative with the disease or even the highest risk combination of HLA alleles, 
making attempts at primary disease prevention difficult. Although survival and patient health 
have improved considerably, particularly in the past 25 years, a cure for type 1 diabetes 
remains elusive.1,2 Additionally, despite advances in technology, glycaemic control for most 
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people with type 1 diabetes is not optimised, and many cannot access modern therapies 
because of the high costs of even basic care.
In 1984, George Eisenbarth developed a conceptual model for the pathogenesis of type 1 
diabetes that is still used nowadays (figure 1).3 The model plots β-cell mass against age, 
highlighting an event sequence starting with predisposing genetic risk, then a precipitating 
environmental trigger that causes islet-specific auto-immunity, followed by β-cell loss, 
dysglycaemia, clinical diabetes, and rapid progression to complete β-cell loss. Although 
useful, this model does not address the increasingly apparent complexity of type 1 diabetes 
pathogenesis. Additionally, the disease pathogenesis is shown by a single line of disease 
course over time; however, at all stages of the disease heterogeneity exists that is not well 
understood.
This Seminar provides a review of type 1 diabetes and the status of research in the field. We 
focus on developments from the past 5 years that highlight the heterogeneity and complexity 
of the disease.
Diagnosis
A diagnosis of diabetes is based on a fasting blood glucose concentration above 7·0 mmol/L 
(126 mg/dL), a random blood glucose concentration above 11·1 mmol/L (200 mg/dL) with 
symptoms, or an abnormal result from an oral glucose tolerance test.5 In the absence of 
symptoms, abnormal glycaemia must be present on two different occasions. A diagnosis of 
diabetes can also be made on the basis of a glycated haemoglobin (HbA1c) concentration 
above 48 mmol/mol (6·5%). However, since dysglycaemia progression can be rapid in 
patients with type 1 diabetes, HbA1c is less sensitive for diagnosis than fasting or stimulated 
blood glucose measurements.5
Children with type 1 diabetes commonly present with symptoms of polyuria, polydipsia, and 
weight loss; approximately a third present with diabetic ketoacidosis.6 The onset of type 1 
diabetes can be more variable in adults, who might not present with the classic symptoms 
seen in children. Although traditional definitions classified type 1 diabetes as juvenile onset, 
the disease can occur at any age, with up to 50% of cases occurring in adulthood.7 As many 
as 50% of adults with type 1 diabetes might be initially misclassified as having type 2 
diabetes.8 Similarly, in conjunction with the epidemic of childhood obesity, type 2 diabetes 
is increasingly common in adolescents (particularly in non-white individuals), and 
monogenic diabetes (eg, maturity diabetes onset of the young) accounts for 1–6% of 
childhood diabetes cases.9–11
Although low C-peptide concentration as a marker of severe endogenous insulin deficiency 
is useful to guide both classification and treatment in cases of diabetes assessed over 3 years 
after clinical diagnosis,12 no single clinical feature can perfectly distinguish type 1 from 
non-type 1 diabetes at diagnosis. Classification depends on an appreciation of other risk 
factors for type 1 versus other subtypes and the integration of clinical features (eg, age of 
diagnosis and body-mass index) with biomarkers (eg, pancreatic autoantibodies).13
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Over 90% of people with newly diagnosed type 1 diabetes have measurable antibodies 
against specific β-cell proteins, including insulin, glutamate decarboxylase, islet antigen 2, 
zinc transporter 8, and tetraspanin-7.14 Birth cohort studies15,16 of individuals with a high 
genetic risk for diabetes have shown a peak incidence of first autoantibody development 
before age 2 years. Most people with a single autoantibody do not progress to type 1 
diabetes, but seroconversion to the presence of two or more serum autoantibodies in children 
is associated with an 84% risk of clinical type 1 diabetes by the age of 18 years (figure 2A).
16
 The high risk of progression in the presence of multiple autoantibodies has led to a 
redefining of type 1 diabetes stages. In this new paradigm, a preclinical stage 1 case of type 
1 diabetes is defined as the presence of two or more autoantibodies, while stages 2 and 3 are 
defined as the progression of metabolic abnormalities from abnormal glycaemia to overt 
diabetes, diagnosed by standard criteria (figure 2B).18 Since the progression from islet 
autoantibody positivity to clinical diabetes could take months or years, defining multiple 
auto-antibody positivity as stage 1 allows targeting of immune interventions to a realistic 
primary outcome and facilitates early life intervention studies.19
Genetics
Type 1 diabetes is a heritable polygenic disease with identical twin concordance of 30–70%,
20
 sibling risk of 6–7%, and a risk of 1–9% for children who have a parent with diabetes.21 
The overall lifetime risk varies greatly by country and geographical region but overall is 
around one in 250 people.22 The disease is slightly more common in men and boys than in 
women and girls.23 Two HLA class 2 haplotypes involved in anti gen presentation, HLA 
DRB1*0301-DQA1*0501-DQ*B10201 (DR3) and HLA DRB1*0401-DQA1*0301-
DQB1*0301 (DR4-DQ8), are linked to approximately 50% of disease heritability and are 
prevalent in white people.24 Other haplotypes are known to reduce type 1 diabetes risk, 
including DRB1*1501-DQA1*0102-DQB1–0602 (DR15-DQ6).24 The mechanisms by 
which these HLA haplotypes interact and alter risk are not completely understood. Different 
HLA associations in other racial groups are recognised but remain poorly characterised.24 
Genome-wide association studies have identified over 60 additional non-HLA loci 
associated with the risk of type 1 diabetes. These variants have been predominantly 
associated with the immune system and highlight pathways that are important in disease 
development—eg, insulin gene expression in the thymus, regulation of T-cell activation, and 
viral responses.24 These HLA and non-HLA genetic associations could identify potential 
targets for future disease-modifying therapies or subgroups of patients who could benefit 
from specific immune interventions.
Historically, people at high risk of type 1 diabetes have been identified for research by HLA 
risk or familial risk, or both.25 By contrast, individual non-HLA loci cannot be used to 
predict type 1 diabetes or discriminate it from other types of diabetes. Combined 
measurement of HLA and non-HLA loci into genetic risk scores could offer improved 
prediction of the risk of developing type 1 diabetes and discrimination of type 1 from type 2 
diabetes.26,27 Furthermore, the continuing fall of genotyping costs could facilitate future 
population-level disease prediction by use of genetic risk scores.19,28
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Epidemiology
Globally, type 1 diabetes is increasing both in incidence and prevalence, with overall annual 
increases in incidence of about 2–3% per year.29,30 US data31 suggest an overall annualised 
incidence from 2001 to 2015 of about 22·9 cases per 100 000 people among those younger 
than 65 years; data from other regions suggest similar incidences.32 The greatest observed 
increases in incidence of type 1 diabetes are among children younger than 15 years, 
particularly in those younger than 5 years.33 These increases cannot be explained by genetic 
changes, implicating environmental or behavioural factors, or both. Many environmental 
exposures are associated with type 1 diabetes, including infant and adult diet, vitamin D 
sufficiency, early-life exposure to viruses associated with islet inflammation (eg, 
enteroviruses), and decreased gut-microbiome diversity.34 Obesity is associated with 
increasing presentation of type 1 diabetes, with β-cell stress potentially providing a 
mechanistic underpinning.34,35 The large differences in the incidence of type 1 diabetes in 
genetically similar populations that are separated by socioeconomic borders36 and the 
increasing incidence of type 1 diabetes in genetically low-risk individuals37 highlight the 
importance of environmental risk factors regardless of genetic background risk. Further 
work is being done to understand the role of gene–environment interactions in the 
pathogenesis of type 1 diabetes, the role of different loci and pathways at different stages of 
the disease, and whether loci that are independent of disease risk could have a role in disease 
progression after development of autoimmunity.38–40 Some data31,41 suggest that the 
observed incidence could be declining in adults or potentially even levelling off across all 
age ranges; worldwide registry data will eventually reveal if this pattern is indeed true.42
The incidence of type 1 diabetes varies by country and by region within countries.31 At 
northern latitudes, people born in the spring are more likely to develop the disease than those 
born in the other seasons.43 The peak incidence of diagnosis is seen in children aged 10–14 
years.31,32 Although many people present with type 1 diabetes in adulthood,44 the higher 
incidence of type 2 diabetes in adulthood compared with type 1 diabetes and the flawed 
criteria for distinguishing these forms of disease make assessment of the incidence of type 1 
diabetes in adults very difficult.23,45 Most people living with type 1 diabetes are adults.46
The immune phenotype of type 1 diabetes
The pathogenesis of type 1 diabetes results from a complex interaction between the 
pancreatic β-cell and innate and adaptive immune systems (figure 3).47 The question of 
whether a trigger for the immune response against β cells exists or whether the immune 
response is a random stochastic event has been a subject of considerable speculation and 
controversy. Several viral infections are associated with type 1 diabetes, with enterovirus 
being one of the most commonly associated infections. Enteroviral major capsid protein 
VP1 and RNA have been detected in islets from people with recent-onset type 1 diabetes,48 
along with hyper-expression of the class 1 major histo compatibility complex49 and other 
indices of viral infection. One possibility is that some people with type 1 diabetes have an 
atypical, chronic viral infection of β cells, leading to chronic inflammation and the 
development of autoimmunity. The viral hypothesis has been difficult to test, although both 
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antiviral therapy and the development of vaccines targeting enteroviruses are being pursued 
for this purpose.
In the field, much effort has been given to the study of the adaptive immune system in type 1 
diabetes by use of assays of peripheral lymphocytes selected for autoreactivity to islet 
antigens. Increased frequency of islet-specific autoreactive CD8+ T lymphocytes and 
decreased regulatory immune function have been associated with type 1 diabetes.50 
Experiments, such as the transfer of type 1 diabetes following non-T-cell depleted allogeneic 
bone-marrow transplantation,51 development of type 1 diabetes in an individual with B-
lymphocyte and antibody deficiency,52 and inherited genetic defects of T-lymphocyte 
function causing type 1 diabetes53 highlight the crucial role of T cells in the 
pathophysiology of type 1 diabetes.54 Almost all studies of peripheral autoimmunity in 
people with type 1 diabetes show overlap of phenotypes seen in the general population, and 
the proportion of islet autoreactive cells present in the periphery is often tiny (only a few 
cells among millions of non-autoreactive cells). As a result, connecting the population of 
autoreactive immune cells that is detectable in blood to the disease process in islets has been 
difficult. A key development has been the isolation of T lymphocytes that are reactive to β-
cell antigen peptides from islets of organ donors with type 1 diabetes.55–57
Histopathologically, these processes are observed as insulitis or immune-infiltrated 
(insulitic) islets.58 CD8+ T lymphocytes are the most common immune cells within insulitic 
lesions, with CD4+ T cells present in lower numbers. Distinct patterns of insulitis that 
stratify with the aggressiveness of β-cell loss and age of diagnosis have been identified in 
insulitic islets.59 Although insulitis is common and intense in animal models of type 1 
diabetes, it is much rarer and more variable in human beings (figure 3).60
The β-cell phenotype of type 1 diabetes
At diagnosis, people with type 1 diabetes have reduced β-cell function compared with 
healthy controls.61 With amelioration of hyperglycaemia, these β cells can have a partial 
recovery of insulin secretory function, leading to a so-called honeymoon period after 
diagnosis with minimal or no exogenous insulin needed. Over time, many of these residual 
cells are lost. However, analysis of pancreatic sections from individuals with long-term type 
1 diabetes show the presence of residual β cells decades after diagnosis.62,63 When sensitive 
C-peptide measure ments are performed, 30–80% of people with long-term type 1 diabetes 
are found to be insulin microsecretors.64–67 So, although endogenous β-cell quantity and 
function decline with longer disease duration, this decline does not progress to a complete 
loss of all β cells.64–67 This finding is noteworthy because in the Diabetes Control and 
Complications Trial68,69 persistent C-peptide secretion was associated with reduced 
development of retinopathy, nephropathy, and hypoglycaemia. Additionally, the persistence 
of C-peptide secretion in people with long-term type 1 diabetes could improve glucagon 
responses to hypoglycaemia.70 Moreover, the presence of residual C-peptide secretion after 
the diagnosis of disease could also increase the possibility of an improved effect of 
interventions targeted at rescuing or augmenting the survival of this residual pool of β cells. 
Analyses of pancreatic specimens from the Network of Pancreatic Organ Donors repository 
have not found evidence of either increased neogenesis or proliferation in pancreatic cells 
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from donors with type 1 diabetes.63 Thus, the mechanisms underlying the persistence of 
residual β cells in people with long-term type 1 diabetes remain unclear. Identifying 
pathways that have allowed these cells to escape the autoimmune attack could yield insight 
into new therapeutic approaches.
β-cell abnormalities might also contribute to type 1 diabetes pathogenesis, leading to the 
notion of so-called β-cell suicide. β-cell HLA class I overexpression is common in 
pancreatic sections from cadaveric donors with type 1 diabetes. This overexpression serves 
as a homing signal for cytotoxic T lymphocytes.49 However, whether this signal is a primary 
β-cell defect or a response to a stimulus (eg, a viral infection) is not yet known. Additionally, 
evidence also exists for increased β-cell endoplasmic reticulum stress linked with 
accelerated β-cell death.71,72 Endoplasmic reticulum stress in β cells has also been 
associated with alterations in mRNA splicing and errors in protein translation and folding; 
the resultant protein products have been proposed as potential immunogenic neoantigens.73
In addition to these defects in the β-cell compartment, alterations in non-endocrine islet cells 
and the exocrine pancreas have also been described (figure 4). These defects include 
abnormalities in the islet extracellular matrix74,75 and in islet innervation and vascularity.
76–78
 Data have also placed a renewed emphasis on the role of exocrine pancreatic pathology 
in type 1 diabetes. Compared with healthy individuals, people with type 1 diabetes have a 
decreased pancreatic weight and volume that continues to decrease with disease duration.
79,80
 This finding could be explained by developmental defects, or pancreatic atrophy in 
response to loss of the paracrine and pro-growth effects of insulin or chronic inflammation, 
or even autoimmune-mediated exocrine destruction. These possibilities are all topics of 
active investigation.
Management of clinical disease
Methods of managing type 1 diabetes continue to improve, and although progress is 
generally slow and incremental, occasionally it is punctuated by rapid change. One such 
moment of change happened in 1993 with the publication of the Diabetes Control and 
Complication Trial.81 This trial and the follow-up observational Epidemiology of Diabetes 
Interventions and Complications trial convincingly showed that achieving and maintaining 
glucose concentrations as close to those seen in people without diabetes as possible leads to 
a reduction in microvascular and cardiovascular type 1 diabetes complications.82
Although insulin remains the mainstay of therapy, new insulin analogues with varying onsets 
and durations of action are widely available. Optimal glycaemic control requires multiple-
dose insulin regimens that mimic physiological insulin release, with basal insulin for 
overnight and between-meal control, plus bolus doses of rapid-acting insulin analogues to 
cover ingested carbohydrate loads and treat hyperglycaemia. Insulin can be taken by 
injection (with an insulin pen if available) or, preferably for many people, with an insulin 
pump.83 Ultra-rapid inhaled insulin is also available, but little enthusiasm for this 
preparation exists because of its fixed dosing (four or eight unit increments only), issues 
with consistent delivery, cost, and the need for pulmonary function testing.84 A faster-acting 
subcutaneously-administered insulin (via injection or infusion) has also recently become 
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available for clinical use. Appropriate insulin use requires frequent dosing adjustments for 
ingested carbohydrates, physical activity, and illness or stress.
While pramlintide is the only non-insulin medication approved for improved glycaemic 
control in patients with type 1 diabetes, metformin, glucagon-like peptide-1 receptor 
agonists, dipeptidyl peptidase-4 inhibitors, and sodium-glucose co-transporter-2 (SGLT2) 
inhibitors have also been used of-label; however, fewer than 5% of patients use these 
medications.85 Metformin, an insulin sensitiser, is the most commonly prescribed drug for 
people with type 1 diabetes who have insulin resistance but it has not been shown to be 
effective in people younger than 18 years who are overweight or obese and have type 1 
diabetes.86 Use of SGLT2 inhibitors is restricted in part because of early reports of 
euglycaemic diabetic ketoacidosis in people with type 1 diabetes treated with these 
compounds. A 2018 meta-analysis of these inhibitors suggests they are safe,87 but more data 
are needed.
Glucagon therapy is also poised to undergo a resurgence in management of type 1 diabetes. 
Although only an emergency kit has been commercially available up until now for cases of 
severe hypoglycaemia leading to seizure or loss of consciousness, nasal and stable liquid 
formulations are being developed. The nasal formulation will be available as a rapid rescue 
therapy only,88 whereas the stable liquid formulation could also be used in small doses for 
exercise and in dual hormone (ie, insulin and glucagon) closed-loop systems.89,90
In the past 13 years, continuous glucose monitoring (CGM) and intermittently viewed CGM 
devices for at-home patient use with minimally invasive devices have become available, 
which have similar accuracy to capillary blood glucose monitors.91 Both CGM and 
intermittently viewed CGM allow examination of glucose concentration patterns over time 
and, although CGM devices still need periodic calibration, they obviate the need for frequent 
capillary blood glucose measurements. CGM is more sophisticated than intermittently 
viewed CGM because it can give the user a warning on the basis of absolute or projected 
glucose values. When CGM is incorporated into hybrid closed-loop insulin-pump systems 
that automatically regulate basal infusion rates, but that require manual delivery of meal 
boluses by trained wearers to cover estimated carbohydrate intakes, substantial 
improvements in glucose variability and overall glycaemic control are seen (figure 5).93 
Combined use of automated insulin delivery and CGM offers the prospect of an artificial 
pancreas with little input from the user. The substantial advances that have been made in 
pump and sensor technology and the increase in the number of trials to test their efficacy 
show that partially or fully automated systems could become a reality.
Guidelines from the American Diabetes Association, International Society for Pediatric and 
Adolescent Diabetes, and Candian Diabetes Association suggest a HbA1c target of less than 
53 mmol/mol (7·0%) for adults and less than 58 mmol/mol (7·5%) in paediatric patients with 
type 1 diabetes;94–96 however, most individuals do not achieve these targets. Although 
setting more aggressive targets is associated with achieving lower HbA1c,97 these targets 
should be individualised on the basis of many factors including comorbidities, patient 
capability and attitude, and available care resources98—eg, even lower targets are often 
prescribed for pregnant women and women anticipating pregnancy than those prescribed to 
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other patients.99 Higher targets might be appropriate for people with hypoglycaemia 
unawareness, history of severe hypoglycaemia, advanced complications, and short life 
expectancy. For optimal outcomes, people with diabetes should be cared for by a 
multidisciplinary care team, including diabetes educators, nurse practitioners, nurses, 
nutritionists, physician assistants, exercise physiologists, social workers, and psychologists. 
To optimise glycaemic control, clinical care with skilled and structured patient education 
and training sessions should be provided—including information on insulin adjustments, 
carbohydrate counting, and optimal use of available technology.100
People with type 1 diabetes also risk developing other autoimmune diseases, sometimes as 
part of a poly-glandular autoimmune syndrome. A study101 from the Type 1 Diabetes 
Exchange clinic registry noted the prevalence of autoimmune disease was 27% in a 
population of over 25 000 people with type 1 diabetes with a mean age of 23 years. The 
most common autoimmune disease is autoimmune thyroiditis (ie, Hashimoto thyroid itis and 
Graves’ disease) followed by coeliac disease. Other associated conditions include collagen-
vascular diseases (eg, rheumatoid arthritis and lupus), autoimmune gastritis or pernicious 
anaemia, vitiligo, and Addison’s disease. Guidelines for the care of people with diabetes 
include periodic screening for these diseases, particularly thyroid and coeliac diseases.102
Complications of type 1 diabetes
The discovery of insulin in 1922 transformed type 1 diabetes from a terminal to a treatable 
disease. Despite the advances in care discussed previously, the disease continues to be 
associated with substantial medical, psychological, and financial burden. Hypoglycaemia 
and ketoacidosis are persistent potentially life-threatening complications. Severe 
hypoglycaemic events requiring treatment assistance from another person occur at rates of 
16–20 per 100 person-years; hypoglycaemic events leading to loss of consciousness or 
seizure occur at a rate of 2–8 per 100 person-years.103–105 Recurrent hypoglycaemia results 
in an increased likelihood of hypoglycaemia unawareness and subsequent severe 
hypoglycaemic events, since recurrent hypoglycaemia reduces the glucose concentration that 
triggers the counter-regulatory responses to return to euglycaemia.106 Hypoglycaemia 
unawareness can improve with edu cation, support, and glucose targets that are aimed at 
avoiding biochemical hypoglycaemia, while maintaining overall metabolic control.107
Hypoglycaemic events are associated with adverse effects on cognitive function,108,109 and 
are associated with 4–10% of type 1 diabetes-related deaths.110–112 Observational studies 
suggest poor diabetes control does not reduce the risk of severe hypoglycaemia.113 Notably, 
rates of severe hypoglycaemic events have been decreasing over time104 and with CGM and 
other advanced diabetes technologies HbA1c can be lowered into the target range without 
increasing the risk of severe hypoglycaemia.114 Treatment in hospital for diabetic 
ketoacidosis occurs at a rate of 1–10 per 100 patient-years in paediatric populations with 
established type 1 diabetes, and accounts for 13–19% of type 1 diabetes-related mortality.
105,110,111
 Incidence of diabetic ketoacidosis is higher among women than among men, and 
among people with higher HbA1c levels than other people with type 1 diabetes.
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Microvascular complications of the disease manifest primarily as retinopathy, neuropathy, 
and nephropathy, but also can affect cognitive function, the heart, and other organs. 
Hyperglycaemia is the primary risk factor for microvascular disease, and reducing HbA1c 
through intensive diabetes management, particularly early during disease, is associated with 
striking (about 70%) reductions in incidence and slower progression of microvascular 
disease. However, differences in HbA1c do not fully explain the variation in the incidence of 
complications and the severity of disease between individuals. Variability in glucose 
concentrations (both during the day and longer term) and glycosylation rates also probably 
have a role in interindividual differences.115,116 Type 1 diabetes during puberty also appears 
to accelerate the development of complications.117
Macrovascular complications of type 1 diabetes include atherosclerosis and thrombosis in 
the heart, peripheral arteries, and brain. By contrast with microvascular complications, the 
risk of cardiovascular complications does not appear to be as attenuated by intensive blood 
sugar control. Diabetic nephropathy, whether manifesting as microalbuminuria, 
macroalbuminuria, or a reduced glomerular filtration rate progressively augments the overall 
risk of macrovascular complications.118 Cardiovascular disease remains the major cause of 
premature morbidity and mortality, with data119,120 suggesting an 8–13-year shorter life 
expectancy for people with type 1 diabetes than for healthy individuals.
People with diabetes might also have both chronic and acute neurocognitive changes that 
include decline in cognitive function with detrimental effects on psychomotor speed, 
cognitive flexibility, attention, and visual perception.121,122 Although the pathophysiology of 
neurocognitive changes is poorly understood, their development has been linked with both 
microvascular and macrovascular changes and changes in brain structure, neuronal loss, and 
cerebral atrophy.123,124 Risk factors include developing diabetes early in life, chronic 
hyperglycaemia, and repeated hypoglycaemia.
In the past 25 years, among people with type 1 diabetes the risks of microvascular and 
macrovascular compli-cations have substantially decreased and outcomes have improved.
125,126
 These improvements have been largely driven by better glycaemic control and 
improved management of associated risk factors—eg, hypertension and hyperlipidaemia. 
Several studies127–130 have identified additional non-glycaemic risk factors for the 
development of complications. Genetic studies have not yielded strong associations between 
specific gene variants and complication status. Low levels of education and income have 
been associated with high risks of both micro-vascular and macrovascular complications.127 
Sex also appears to modify risk, since women with type 1 diabetes have been shown to have 
higher rates of all-cause premature mortality and vascular events than do men with type 1 
diabetes.128 In the past 5 years, new technologies have been designed to attempt to better 
predict future risk and complications by combining risk factors into probability models. Two 
examples are the QDiabetes129 and QRISK3130 web calculators that were developed with a 
prospective general practice dataset of 803 044 people with diabetes (44 440 with type 1 
diabetes). These calculators can be used to predict 10-year risk for microvascular and 
macrovascular complications. However, continued work is needed in this area to combine 
prediction models with disease-specific bio- markers and disease-modifying therapies that 
can prevent sequelae.
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An additional noteworthy complication of type 1 diabetes is the patient-reported burden of 
adverse also their family, friends, and caregivers.131 Fear of hypoglycaemia is a prevalent 
issue, particularly for the families of very young children with type 1 diabetes.132 
Furthermore, poor quality of life is predictive of subsequent poor glycaemic control.133
Disease-modifying therapies
For over 30 years, most efforts to cure type 1 diabetes have focused on altering the immune 
system’s attack on β cells. This approach began with trials of ciclosporin, an 
immunosuppressant that was given to inhibit T-cell activation. Although ciclosporin was 
unable to induce a durable disease remission, insulin requirements of patients decreased 
during active treatment, generating enthusiasm that immune modulation could treat type 1 
diabetes.134–136 Subsequently, other strategies have been tested in both primary and 
secondary prevention paradigms. Most efforts have focused broadly on tolerance induction 
by use of antigens or modulation of T-lymphocyte, B-lymphocyte, and cytokine responses. 
Some primary prevention studies have also used dietary approaches.137,138
Antigen-based trials have used various forms of glutamate decarboxylase (GAD) protein, 
which have shown mixed but mostly negative results.139–141 The Diabetes Prevention Trial
—Type 1, tested whether oral or parental insulin prevented the development of type 1 
diabetes in people who were autoantibody positive. Neither approach reduced diabetes 
development, but subgroup analyses suggested a benefit of oral insulin in individuals with 
the highest titres of insulin auto-antibodies.142,143 Based on this finding, the Type 1 Diabetes 
TrialNet Network completed a trial144 of low-dose oral insulin in a second cohort of 
individuals who were autoantibody positive with similar insulin autoantibody profiles, but 
this trial was also negative. Negative results were also observed in another trial investigating 
intranasal insulin.145
Personalised strategies for tolerance induction are now also being pursued. One study tested 
repeated intradermal doses of a specific proinsulin peptide fragment in people with the HLA 
DRB1*0401 genotype,146 for whom this peptide was identified to be specifically 
immunogenic. Clinical trials at diagnosis have also tested approaches aimed at modulating 
T-cell and B-cell responses. Despite many attempts at immune intervention, only four 
categories of drugs have shown efficacy in preserving C-peptide secretion in recent onset 
type 1 diabetes in randomised placebocontrolled trials. These drugs include a monoclonal 
antibody against the B-cell CD20 receptor (rituximab),147 monoclonal antibodies against the 
T-cell CD3 receptor (teplizumab148,149 and otelixizumab150), cytotoxic T-lymphocyte 
protein 4 (CTLA4)-immunoglobulin-mediated co-stimulatory blockade with abatacept,151 
and alefacept,152 which is a fusion protein that binds CD2 and targets CD4+ and CD8+ 
effector memory T cells. Although the phase 2 trials of these drugs met their primary or 
secondary endpoints, defined as an improvement in the C-peptide area-under-the-curve 
response during a mixed meal tolerance test, no drug has yet been able to induce insulin 
independence or progressed to a positive phase 3 trial that was translatable into clinical care. 
This gap in translating results from trials into clinical practice could highlight the need for 
alternative strategies. Combinatorial approaches that modulate multiple aspects of the 
immune response could result in better efficacy. For example, low-dose anti-thymocyte 
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globulin in combination with granulocyte colony-stimulating factor has shown early and 
sustained efficacy in pilot studies153,154 and is being tested in a phase 2 study () in recent-
onset type 1 diabetes. Another approach is to intervene earlier in the disease process, at a 
time when greater β-cell mass remains. To this end, abatacept () and teplizumab () are being 
tested in stage 1 and stage 2 type 1 diabetes through the TrialNet Network. Even modest 
preservation of β-cell function could have long-term benefits, and better glycaemic control 
early in the disease course could mitigate the likelihood of complications.155–157
One potential future therapy for type 1 diabetes is with replacement of β cells from an 
external source. Pancreas transplants have been performed for over 50 years and have 
become a standard-of-care treatment in individuals who have developed end-stage renal 
failure and require kidney transplantation.158 Simultaneous kidney and pancreas 
transplantation in experienced centres can offer an up to 80% chance of insulin 
independence for over 5 years, but there is substantial surgical risk, and the requirement of 
immunosuppression.159 Islet transplantation is a low-risk procedure, with donor islets 
infused into the liver via the portal vein. Shapiro and colleagues’ landmark work, by use of a 
steroid free Edmonton Protocol,160 showed that islet transplantation could achieve insulin 
independence and offered an example of a successful and low-risk cell-based therapy. 
However, only a minority of islet transplant recipients achieve durable insulin independence. 
Moreover, morbidity associated with immunosuppression and limitations in the supply of 
donor islets restricts the number of people who can benefit from islet transplantation.161 
Currently, islet transplantation is used in a small subset of patients who have extremely 
severe hypoglycaemic unawareness. Even if insulin independence is not achieved, severe 
life-threatening hypoglycaemia can be prevented with minimal islet transplant function.
162,163
Cell therapy as a potential cure for type 1 diabetes remains a field of great interest.2 
Considerable effort has been focused on protocols to generate functional and glucose-
responsive β cells from human embryonic stem cells or induced pluripotent stem cells from 
living donors. This approach offers the possibility of a limitless source of β cells that could 
be delivered in a semipermeable device that would permit functional insulin secretion but 
avoid the need for immuno-suppression.164 Several small molecules, growth factors, 
hormones, and nutrients have been shown to promote modest β-cell neogenesis and 
proliferation. However, most positive results come from animal models and have been 
difficult to replicate in human studies. While stem-cell-based therapies and neogenesis are a 
source of hope for potential cures, they are not realistic treatments in the immediate future.2
Other novel approaches include autologous haemopoietic stem-cell transplantation165,166 
and autologous T-regulatory cell administration.167–169 In response to growing evidence 
highlighting an active role for the β cell in disease pathogenesis, several ongoing trials are 
testing drugs that have successfully targeted β-cell stress responses in mouse models of 
diabetes.170
DiMeglio et al. Page 11
Lancet. Author manuscript; available in PMC 2019 July 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Conclusions
Over the past 50 years, people with type 1 diabetes and their medical-care providers have 
been tantalised with optimism and subsequently disappointed at the seemingly unobtainable 
cure on the horizon. However, this long journey has been punctuated by several pivotal 
successes, including the discovery of insulin in 1922, the first pancreatic transplantation in 
1966,171 the first insulin-pump studies, the first immunomodulatory trial in 1986,136 and the 
first definitive evidence linking glycaemic control with complication status in 1993.81 The 
past 25 years has brought an upsurge of technological advances, including designer insulin 
analogues, smart insulin pumps, continuous glucose sensors, and closed-loop insulin 
delivery systems.
Clinicians, investigators, and patients have gained a better appreciation of the true 
complexity of type 1 diabetes, and humility in the face of many unsuccessful trials aimed at 
inducing a durable disease remission. While scientists continue to untangle the complicated 
pathogenesis of the disease, patients and health-care providers should focus on advocating 
for improved access to modern advances in diabetes care, especially for affordable insulin 
analogues and technologies that can reduce the burden of managing this chronic disease. 
When insulin was discovered, the University of Toronto freely licensed the right to 
manufacture the drug; yet, people in resource-limited environments continue to die because 
they have no access to insulin.172
Additionally, crucial research must continue into strategies to prevent disease onset and 
preserve or restore β-cell function. These approaches offer the promise of ameliorating or 
eliminating disease complications, and greatly improving outcomes for those who have the 
disease. Continued development of new low-cost, low-burden, and highly effective therapies 
to improve glycaemic control is also needed. These approaches could include investigation 
into the effects of different dietary composition on glycaemic outcomes, and the safety and 
efficacy of open-source patient-designed artificial pancreas innovations. Given observed 
differences in care, health-care providers must be committed to initiatives for continuous 
quality improvement, with a focus on increasing uptake and implementation of best 
standards of care. A greater focus on patient-centred outcomes has been present in trials, and 
further exploration of these important endpoints is also crucial. If stakeholders in the field 
concentrate on the areas that are most likely to have a long-term effect, management of type 
1 diabetes is poised to undergo further radical transformation.
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Search strategy and selection criteria
We searched MEDLINE for publications in English published between Jan 1, 2014, and 
March 1, 2018, using the term “type 1 diabetes” and MEDLINE subheadings and 
selected papers on the basis of our opinion of their scientific importance. Research 
published since the 2014 Lancet Seminar on this topic was given particular attention. We 
provide an overview of type 1 diabetes focusing on updating the reader on recent 
advances and controversies.
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Figure 1: Challenges to the Eisenbarth model of the natural history of type 1 diabetes
Key events of the Eisenbarth model3 over the course of the disease (measured in years) are 
shown by dotted lines at different time points. Challenges to this model, taking into account 
the increasing complexity of type 1 diabetes, include the following: precipitating immune 
events that might occur prenatally (A); large variation in starting β-cell mass and function, 
defects in one or both could be developmentally programmed (B); initiation of 
autoimmunity is measured by autoantibodies, but other immunological abnormalities 
probably precede the presence of detectable pancreatic antibodies (C); the patient’s 
environment could affect their entire disease course (D); β-cell loss could relapse or remit 
(E); dysglycaemia occurs before clinical diagnosis (F); decline in β-cell function might not 
mirror decline in β-cell mass—methods to measure β-cell mass have not been established 
(G); and residual C-peptide is detectable in many people who have long duration type 1 
diabetes (H). Furthermore, progression through stages A–C is heterogeneous, and will be 
affected by immune, genetic, environment, and key demographic features (ie, age, body-
mass index). Adapted from Atkinson et al.4
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Figure 2: Factors contributing and disease progression to type 1 diabetes
(A) The probability of developing diabetes in childhood stratified by the number of islet 
antibodies. In a study by Zeigler and colleagues,16 13 377 children were identified as at risk 
in the newborn or infant period on the basis of high-risk HLA genotypes or having a relative 
with type 1 diabetes, or both, and were followed-up regularly. The numbers at risk are the 
number of children receiving follow-up at ages 0, 5, 10, 15, and 20 years. Adapted from 
Ziegler et al16 with permission of the American Medical Association. (B) Type 1 diabetes 
progression and stages of type 1 diabetes. Stage 1 is the start of type 1 diabetes, marked by 
individuals having two or more diabetes-related autoantibodies and normal blood sugar 
concentrations. In stage 2, individuals have dysglycaemia without symptoms. Stage 3 is the 
time of clinical diagnosis. Reproduced from Greenbaum et al,17 with permission from the 
American Diabetes Association. T1D=type 1 diabetes.
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Figure 3: The immunopathogenesis of type 1 diabetes
The development of type 1 diabetes is thought to be initiated by the presentation of β-cell 
peptides by antigen-presenting cell (APCs). APCs bearing these autoantigens migrate to the 
pancreatic lymph nodes where they interact with autoreactive CD4+ T lymphocytes, which 
in turn mediate the activation of autoreactive CD8+T cells (A). These activated CD8+ T 
cells return to the islet and lyse β cells expressing immunogenic self-antigens on major 
histocompatibility complex class I surface molecules (B). β-cell destruction is further 
exacerbated by the release of proinflammatory cytokines and reactive oxygen species from 
innate immune cells (macrophages, natural killer cells, and neutrophils; C). This entire 
process is amplified by defects in regulatory T lymphocytes, which do not effectively 
suppress autoimmunity (D). Activated T cells within the pancreatic lymph node also 
stimulate B lymphocytes to produce autoantibodies against β-cell proteins. These 
autoantibodies can be measured in circulation and are considered a defining biomarker of 
type 1 diabetes (E).
DiMeglio et al. Page 25
Lancet. Author manuscript; available in PMC 2019 July 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4: Pancreatic and islet abnormalities in type 1 diabetes
(A) Type 1 diabetes is characterised by a variety of abnormalities that involve both the islet 
and the exocrine pancreas. The hallmark of type 1 diabetes is loss of insulin-producing β 
cells and immune infiltration of islets. However, the presence of insulitis, even within an 
individual pancreas, can be highly variable. (B) Immunofluorescent image of an insulitic 
islet from a cadaveric donor with long-term type 1 diabetes. Insulin is shown in blue and 
CD8+ T cells surrounding the islet are shown in yellow. (C) Haematoxylin and eosin 
staining of an islet from a cadaveric donor that exhibits a classic pattern of insulitis. The islet 
is circled with a yellow dotted line. The infiltrating immune cells are circled in red and 
indicated by arrows. (D) Haematoxylin and eosin staining of an islet, circled in yellow 
dotted line, from a cadaveric donor with long-term type 1 diabetes without any discernible 
immune infiltrate. By contrast with the islet in (C), this islet has evidence of peri-islet 
fibrosis as shown circled in red and indicated by arrows. Images B–D courtesy of M 
Campbell-Thompson, University of Florida, Gainesville, FL, USA.
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Figure 5: Glucose concentrations in patients with type 1 diabetes with a hybrid closed-loop 
system, before and after use, over 24 h
Sensor glucose profiles from 124 people with type 1 diabetes, of which 30 were adolescents 
(14–21 years; A) and 94 were adults (22–75 years; B), before (during run-in phase) and 
during the study phase using the Medtronic MiniMed 670 g hybrid closed-loop system 
(Medtronic, Northridge CA, USA) under clinical trial conditions. Median and IQR of sensor 
glucose values are given as a green line and band for the run-in phase, and a pink line and 
band for the study phase, respectively. In the run-in phase, the hybrid closed-loop system 
was in manual mode, with participants making all treatment decisions except for the pump 
automatically suspending before senor glucose concentrations became too low. In the study 
phase, the hybrid closed-loop system was in auto mode. Participants had less variability in 
their blood glucose concentration during auto mode. Reproduced from Garg et al,92 with 
permission from Mary Ann Liebert.
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